-
1 Comment
PRA Health Sciences, Inc is currently in a long term uptrend where the price is trading 19.4% above its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.2.
PRA Health Sciences, Inc's total revenue rose by 9.1% to $873M since the same quarter in the previous year.
Its net income has dropped by 31.5% to $51M since the same quarter in the previous year.
Finally, its free cash flow fell by 15.6% to $147M since the same quarter in the previous year.
Based on the above factors, PRA Health Sciences, Inc gets an overall score of 3/5.
ISIN | US69354M1080 |
---|---|
Industry | Diagnostics & Research |
Sector | Healthcare |
CurrencyCode | USD |
Exchange | NASDAQ |
Beta | 1.33 |
---|---|
Market Cap | 11B |
Dividend Yield | 0.0% |
Target Price | 165.4 |
PE Ratio | 50.52 |
PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. It operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, as well as bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include market intelligence services, such as targeting and compensation, and pharmaceutical audit suite services; consulting and services comprising brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services that allow clients to access and analyze Symphony Health and integrated third-party data. PRA Health Sciences, Inc. conducts clinical trials in the areas of pharmaceutical development, including oncology, immunology, central nervous system, inflammation, respiratory, cardiometabolic, and infectious diseases. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina. As of July 1, 2021, PRA Health Sciences, Inc. operates as a subsidiary of ICON Public Limited Company.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for PRAH using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024